Respiratory syncytial virus represents a premier driver of severe lower respiratory infections and pediatric hospital admissions across the globe. Consequently, maternal RSV vaccination has emerged as a groundbreaking public health milestone designed to transfer protective neutralizing antibodies across the placenta to neonates. Although clinical trials demonstrate excellent prophylactic efficacy, real-world disease prevention depends entirely on equitable maternal uptake. A cross-sectional investigation from Argentina evaluated initial clinical coverage and exposed critical structural and informational barriers during pregnancy. Therefore, clinicians must understand these determinants to optimize maternal immunization delivery in routine practice.

Maternal RSV Vaccination and Neonatal Bronchiolitis Prevention

Respiratory syncytial virus causes significant annual morbidity, frequently leading to acute bronchiolitis, viral pneumonia, and intensive care admissions among neonates. Historically, medical teams managed infant RSV using supportive respiratory care, supplemental oxygen, and costly monoclonal antibodies reserved for high-risk preterm infants. Consequently, healthy full-term infants remained highly vulnerable to seasonal viral surges during their first six months of life. Maternal immunization provides an elegant immunological solution by converting late gestation into an active window for infant prophylaxis.

Furthermore, clinical trials demonstrate that administering the bivalent prefusion F vaccine between 32 and 36 weeks of gestation reduces medically attended severe lower respiratory tract disease by over 70%. When an expectant mother receives the injection, active transplacental transfer supplies the fetal circulation with robust levels of protective immunoglobulin G antibodies. Thus, the newborn acquires immediate passive humoral defense prior to birth. Real-world surveillance programs corroborate these clinical trial findings, revealing substantial decreases in seasonal infant hospitalizations. Therefore, professional obstetric and pediatric societies increasingly recommend this proactive maternal strategy as standard antenatal care.

Evidence on Coverage and Determinants of Immunization Uptake

In 2024, Argentina implemented a national public maternal immunization initiative to protect infants against severe respiratory infections. To evaluate early program execution, Souto and colleagues conducted a cross-sectional study surveying 216 eligible postpartum mothers. Strikingly, overall coverage reached only 43.7%, indicating that regulatory approval and product availability do not guarantee universal uptake. Therefore, understanding specific operational impediments is vital for improving international immunization programs.

In addition, researchers analyzed maternal barriers across structural, informational, emotional, and social categories. Univariate analysis revealed that women who attended fewer than five prenatal visits experienced significantly lower vaccination rates. Similarly, mothers who did not receive clear clinical counseling from their antenatal providers demonstrated notably lower uptake. Most importantly, multivariate logistic regression demonstrated that direct knowledge regarding the vaccine was the sole independent predictor of successful immunization. Specifically, informed mothers were 3.4 times more likely to get vaccinated compared to uninformed peers. Consequently, informational awareness represents the single most decisive factor driving maternal immunization.

Addressing Structural and Informational Obstacles in Antenatal Care

Health systems often introduce novel prenatal immunizations without restructuring clinical workflows, which creates profound structural barriers for pregnant patients. For example, fragmented prenatal clinics frequently separate obstetric evaluations from vaccine administration. When expectant mothers must schedule separate appointments or visit off-site pharmacies, logistical inconveniences lead to substantial attrition. Furthermore, crowded antenatal clinics force healthcare providers to rush consultations, leaving minimal time for preventive counseling.

Similarly, informational hurdles severely compromise vaccine confidence among pregnant women. Expectant mothers encounter pervasive misinformation on social platforms, which fuels anxiety regarding pharmaceutical safety during gestation. In the absence of proactive physician explanations, these emotional worries often translate into vaccine deferral or refusal. However, transparent clinical dialogue readily dispels misconceptions by explaining the well-established maternal safety profile and transplacental mechanics. Therefore, antenatal care units must provide seamless point-of-care immunization during standard third-trimester appointments. In addition, distributing concise educational brochures during waiting periods equips mothers with the knowledge needed to make confident decisions.

The Indispensable Role of Clinician Recommendation

Clinical evidence consistently highlights provider recommendation as the most influential external determinant of maternal vaccine acceptance. Expectant mothers place exceptional trust in their obstetricians, midwives, and family physicians when assessing gestational interventions. Therefore, when a healthcare provider issues a direct, affirmative endorsement, maternal vaccine acceptance rates rise dramatically. Conversely, clinician silence frequently creates passive hesitation, as patients assume unmentioned vaccines are either unnecessary or experimental.

Moreover, physicians must proactively frame vaccination as an act of infant protection rather than an invasive maternal treatment. Clinicians can explain that maternal vaccination delivers ready-made antibodies that shield infants during their most fragile early months. Furthermore, healthcare teams should leverage standardized digital prompts in electronic health records to ensure consistent counseling at 32 weeks of gestation. When multidisciplinary teams coordinate their messaging across prenatal visits, maternal confidence strengthens considerably. Consequently, structured clinician advocacy transforms hesitant patients into informed, proactive participants in infant disease prevention.

Clinical Implications for Low- and Middle-Income Countries

The lessons derived from Latin America offer vital guidance for health systems across low- and middle-income countries, including India. In these regions, respiratory syncytial virus generates substantial pediatric morbidity and strains inpatient intensive care resources during seasonal peaks. Introducing maternal immunization offers an exceptional opportunity to curb infant mortality and reduce hospital expenditures. However, public health authorities cannot rely on passive distribution strategies alone.

Instead, health ministries must strengthen primary healthcare infrastructure, secure robust cold-chain logistics, and ensure uninterrupted local supply chains. Simultaneously, medical societies should deliver targeted continuing education to community healthcare workers, obstetricians, and pediatricians. Equipping frontline providers with comprehensive scientific training enables them to address community doubts with clarity and empathy. Furthermore, integrating maternal immunization tracking into existing antenatal registers will prevent missed opportunities. By combining clinical advocacy, streamlined delivery, and rigorous patient education, healthcare systems can maximize coverage and protect millions of vulnerable infants.

At what gestational age should maternal RSV vaccination be administered?

Clinicians generally administer the bivalent maternal RSV vaccine between 32 and 36 weeks of gestation. This specific window maximizes transplacental transfer of neutralizing maternal antibodies to the fetus while mitigating any theoretical preterm risks. Consequently, infants acquire passive protective immunity before delivery. If mothers deliver at least two weeks post-immunization, neonates maintain robust protection against severe lower respiratory tract disease during their initial vulnerable months of life.

How does prenatal maternal RSV vaccination protect vulnerable neonates?

Maternal immunization works by stimulating high titers of maternal immunoglobulin G antibodies against the RSV prefusion F protein. The placenta actively transfers these protective immunoglobulins into fetal circulation during the third trimester. Therefore, the newborn enters life with pre-existing passive immunity against respiratory syncytial virus. This circulating antibody reservoir significantly reduces the incidence of viral bronchiolitis and infant intensive care admissions during the initial six months after birth.

What strategies best improve maternal RSV vaccination uptake during antenatal visits?

Obstetricians and primary care clinicians must integrate proactive vaccine discussions directly into routine third-trimester prenatal consultations. Specifically, clinicians should clearly explain neonatal bronchiolitis risks and confirm vaccine safety to resolve patient hesitancy. Moreover, healthcare systems should reduce structural barriers by providing same-day immunizations during routine visits. Establishing multimodal patient educational campaigns substantially enhances maternal health literacy and directly improves overall immunization coverage in diverse patient populations.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical or healthcare advice. Consult a healthcare professional for diagnosis or treatment options. Refer to the latest local and national guidelines for clinical practice.

References

1. Souto SM et al. Perceived barriers to respiratory syncytial virus vaccination and vaccination coverage among pregnant women: A cross-sectional study. Arch Argent Pediatr. 2026 Oct 22. doi: 10.5546/aap.2026-11029.eng. PMID: 42898619.
2. Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023;388(16):1451-1464.
3. World Health Organization. WHO preferred product characteristics for respiratory syncytial virus (RSV) vaccines. Geneva: World Health Organization; 2021.
4. Savitzky C, Perez G, Rodriguez PE, et al. Real-world effectiveness of RSVpreF vaccination during pregnancy against infant hospitalisation. Lancet Infect Dis. 2025;25(5):540-549.